Drug intelligence / Profile preview

ALD1910 + sumatriptan

Development stage: Preclinical
Lead developer: Lundbeck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous (for ALD1910, As mAb), Oral, Intranasal, Subcutaneous (for Sumatriptan)

Overview

**ALD1910 + sumatriptan** is an investigational combination of a monoclonal antibody (ALD1910) and a small molecule triptan (sumatriptan), both designed for the treatment of migraine. ALD1910 is a high-affinity, neutralizing monoclonal antibody targeting both forms of pituitary adenylate cyclase-activating peptide (PACAP-38 and PACAP-27), thereby blocking PACAP signaling pathways implicated in migraine pathophysiology[2][4]. Sumatriptan is a selective serotonin (5-HT1B/1D) receptor agonist ("triptan") that treats acute migraine attacks by inducing vasoconstriction of intracranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides[1]. This combination would theoretically provide both acute relief (via sumatriptan) and potential prevention or modulation of migraine triggers at the pathway level (via ALD1910), targeting two distinct and complementary mechanisms underlying migraine attacks.

Brand names: Imitrex
Other names: sumatriptan

Targets

PACAP (Pituitary adenylate cyclase-activating polypeptide)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1F (Serotonin 5-HT1F receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on ALD1910 + sumatriptan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALD1910 + sumatriptan.

Explore the full profile